Opinion|Videos|October 28, 2024
Optimizing Multidisciplinary Care for BCG-Naive, High-Risk NMIBC
Key Takeaways
- Multidisciplinary teams should integrate oncologists and urologists, emphasizing patient-centered care for high-risk non–muscle-invasive bladder cancer.
- Global preparation involves understanding diverse market needs and ensuring access to resources and education.
Panelists discuss the characteristics of an ideal multidisciplinary team for managing BCG-naive, high-risk non–muscle-invasive bladder cancer (NMIBC), emphasizing the need for oncologists and urologists to collaboratively prepare for successful patient outcomes across different markets, while also identifying necessary educational resources and highlighting adverse events that require attention in preparation for product launches.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What does an ideal multidisciplinary team look like in BCG-naive, high-risk non–muscle-invasive bladder cancer? How can the team (oncologists & urologists) prepare globally (in different markets) to set up patients for the most success?
- What education or resources are needed prior to the launch of these products or prior to this evolving landscape to prepare for the launches?
- What adverse events need attention and education as part of the prelaunch preparation?
- Closing thoughts from each of the panelists.
Advertisement
Related to this article
Jeffrey M. Spier, MD, discusses how fatigue may impact patient quality-of-life and when dose reduction may be an appropriate treatment strategy.
This approval expands the perioperative use of pembrolizumab plus enfortumab vedotin to all patients with MIBC, regardless of cisplatin eligibility.
Take a look through some of the notable data presentations at this year's ESMO Congress.
The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
The agency issued a PDUFA target action date of June 14, 2027.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Casdatifan shows activity across treatment settings in advanced ccRCC
3
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
4
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
5